Abnormal MYCN amplification and the consequent overexpression of the oncoprotein, N-Myc, which occurs in 20%–25% of patients with neuroblastoma and 50% of high-risk cases, is the most important promoting factor and the best-characterized genetic marker for poor prognosis of neuroblastoma (37–39). Here, MYCN is linked to neuroblastoma.